- Home
- CTMX vs THQ Comparison
CTMX vs THQ Comparison
Compare CTMX & THQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- THQ
- Stock Information
- Founded
- CTMX 2008
- THQ 2014
- Country
- CTMX United States
- THQ United States
- Employees
- CTMX N/A
- THQ N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- THQ Finance Companies
- Sector
- CTMX Health Care
- THQ Finance
- Exchange
- CTMX Nasdaq
- THQ Nasdaq
- Market Cap
- CTMX 596.2M
- THQ 714.6M
- IPO Year
- CTMX 2015
- THQ N/A
- Fundamental
- Price
- CTMX $3.32
- THQ $18.20
- Analyst Decision
- CTMX Strong Buy
- THQ
- Analyst Count
- CTMX 5
- THQ 0
- Target Price
- CTMX $5.80
- THQ N/A
- AVG Volume (30 Days)
- CTMX 3.0M
- THQ 158.9K
- Earning Date
- CTMX 11-07-2025
- THQ 01-01-0001
- Dividend Yield
- CTMX N/A
- THQ 7.53%
- EPS Growth
- CTMX 263.20
- THQ N/A
- EPS
- CTMX 0.49
- THQ N/A
- Revenue
- CTMX $141,100,000.00
- THQ N/A
- Revenue This Year
- CTMX N/A
- THQ N/A
- Revenue Next Year
- CTMX N/A
- THQ N/A
- P/E Ratio
- CTMX $6.79
- THQ N/A
- Revenue Growth
- CTMX 18.01
- THQ N/A
- 52 Week Low
- CTMX $0.40
- THQ $15.29
- 52 Week High
- CTMX $3.91
- THQ $20.38
- Technical
- Relative Strength Index (RSI)
- CTMX 55.87
- THQ 64.23
- Support Level
- CTMX $3.21
- THQ $18.11
- Resistance Level
- CTMX $3.91
- THQ $18.31
- Average True Range (ATR)
- CTMX 0.26
- THQ 0.22
- MACD
- CTMX -0.06
- THQ 0.00
- Stochastic Oscillator
- CTMX 30.59
- THQ 79.73
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About THQ abrdn Healthcare Opportunities Fund Shares of Beneficial Interest
abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. The fund's investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies.